医学
嵌合抗原受体
内科学
胃肠病学
免疫学
T细胞
肿瘤科
病毒学
免疫系统
作者
Carlos Solano de la Asunción,Rafael Hernani,Eliseo Albert,María Dolores Gómez,Estela Giménez,Ana Benzaquén,Eva María Gonzalez‐Barberá,Juan Carlos Hernández‐Boluda,Ariadna Pérez,José Luís Piñana,Pedro Chorão,Manuel Guerreiro,Juan Montoro,Jaime Sanz,Carlos Solano,David Navarro
标识
DOI:10.1016/j.cmi.2023.05.010
摘要
Cytomegalovirus (CMV) DNAemia may develop in a large percentage (up to 45%) of CMV-seropositive patients undergoing CD19-directed chimeric antigen receptor T-cell therapy [ [1] Chen G. Herr M. Nowak J. Ho C. Almyroudis N. Attwood K. et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023; 108: 615-620https://doi.org/10.3324/haematol.2022.281719 Crossref PubMed Scopus (2) Google Scholar , [2] Márquez-Algaba E. Iacoboni G. Pernas B. Esperalba J. Los Arcos I. Navarro V. et al. Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2022; 28: 851.e1-851.e8https://doi.org/10.1016/j.jtct.2022.09.007 Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar ] and may contribute to worsen clinical outcomes [ [1] Chen G. Herr M. Nowak J. Ho C. Almyroudis N. Attwood K. et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023; 108: 615-620https://doi.org/10.3324/haematol.2022.281719 Crossref PubMed Scopus (2) Google Scholar ]. Here by not administering preemptive antiviral therapy (PET) at low plasma CMV DNA loads (<1500 IU/mL, following local standard practice guidelines) we could gain a further insight on the kinetics of CMV DNAemia in these patients. In this retrospective, observational study, 51 consecutive CMV-seropositive patients (median age, 62 years; range, 22–79; 26 male) were included (Table S1). This study was approved by the respective research ethics committees, and informed consent was obtained from participants.
科研通智能强力驱动
Strongly Powered by AbleSci AI